Back to Authors

Doxtader, Erika

https://orcid.org/0000-0002-6425-6537

Mayo Clinic

Cleveland Clinic

Citations 2

Oil Red O Staining of Pulmonary Macrophages in Bronchoalveolar Lavage Specimens Is Not Specific for Vaping-Associated Lung Injury
Thangaiah, Judith Jebastin, Booth, Christine N. , Brainard, Jennifer , Elsheikh, Tarik M. , Ondrejka, Sarah L. , Thilagar, Bright , Mukhopadhyay, Sanjay , Jebastin, Judith A S , Ondrejka, Sarah , Thilagar, Bright P. , Mukhopadhyay, Sanjay , Reynolds, Jordan , Doxtader, Erika

American Journal of Clinical Pathology | October 12, 2022 | Volume: 158 | Issue: 6 | Pages: 723-729

10.1093/ajcp/aqac118 Get It

Abstract Objectives Oil Red O (ORO) positivity in bronchoalveolar lavage (BAL) fluid macrophages in the setting of e-cigarette, or vaping, product use–associated acute lung injury (EVALI) has been frequently requested by clinicians based on rare reports and subsequent US Centers for Disease Control and Prevention guidelines. The aim of this study was to determine the specificity of ORO staining in BAL specimens with disease states other than EVALI. Methods Consecutive BAL specimens (October-December 2019) were stained with ORO. The lipid-laden macrophage index (LLMI) was calculated for each case. Results We studied BAL samples from 50 patients. Indications for BAL were surveillance bronchoscopy for lung transplantation (27/50), suspected infection (12/50), sarcoidosis/suspected sarcoidosis (3/50), nodules or ground-glass opacities (3/50), hemoptysis (2/50), asthma or eosinophilic pneumonia (2/50), and idiopathic pulmonary fibrosis (1/50). ORO staining was seen in BAL fluid macrophages in 45 of 50 cases (focal in 18, moderate in 23, diffuse in 4); LLMI ranged from 0 to 218. Using a threshold of LLMI of 85 or higher as positive, ORO was positive in 7 of 50 (14%) cases (range, 85-218). Conclusions ORO staining in BAL fluid macrophages is not specific for EVALI. Even when an LLMI of 85 or higher is used as a threshold for positivity, ORO positivity occurs in a significant subset of non–vaping-related cases.
E‐cigarette or vaping product use–associated lung injury: What is the role of cytologic assessment?
Saqi, Anjali , Butt, Yasmeen M. , Doxtader, Erika , Heymann, Jonas J. , Larsen, Brandon T. , Moreira, André L. , Patel, Ami , Reynolds, Jordan , Sung, Simon , Crapanzano, John P. , Butt, Yasmeen, Doxtader, Erika , Heymann, Jonas J , Sung, Simon , Saqi, Anjali , Reynolds, Jordan P , Mukhopadhyay, Sanjay

Cancer Cytopathology | January 27, 2020 | Volume: 128 | Issue: 6 | Pages: 371-380

10.1002/cncy.22237 Get It

Greater than 2000 cases of vaping‐associated pulmonary injury and 39 deaths reported in the United States have heightened public awareness and assumed major public health significance over recent months. Currently, knowledge of the effects of various vaping agents on the respiratory tract is in its infancy. Additional understanding of the agents implicated in these lung injuries as well as a correlation between bronchoalveolar lavage and lung biopsy samples is required.